WallStSmart

Nutanix Inc (NTNX)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nutanix Inc generates 937% more annual revenue ($2.69B vs $258.90M). NTNX leads profitability with a 9.9% profit margin vs -15.5%. NTNX earns a higher WallStSmart Score of 57/100 (C).

NTNX

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 5.5Value: 6.7Quality: 6.0
Piotroski: 4/9Altman Z: -0.72

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NTNXUndervalued (+19.7%)

Margin of Safety

+19.7%

Fair Value

$51.62

Current Price

$40.89

$10.73 discount

UndervaluedFair: $51.62Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NTNX3 strengths · Avg: 9.3/10
EPS GrowthGrowth
83.2%10/10

Earnings expanding 83.2% YoY

Debt/EquityHealth
-2.2110/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.938/10

Growing faster than its price suggests

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

NTNX3 concerns · Avg: 2.3/10
Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

P/E RatioValuation
44.9x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
-0.722/10

Distress zone — elevated risk

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : NTNX

The strongest argument for NTNX centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 10.4% demonstrates continued momentum. PEG of 0.93 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : NTNX

The primary concerns for NTNX are Return on Equity, P/E Ratio, Altman Z-Score. A P/E of 44.9x leaves little room for execution misses.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

NTNX profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NTNX scores higher overall (57/100 vs 41/100) and 10.4% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nutanix Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Nutanix, Inc. develops and provides an enterprise cloud platform in North America, Europe, Asia Pacific, the Middle East, Latin America, and Africa. The company is headquartered in San Jose, California.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?